鳞状细胞癌抗原、肿瘤相关胰蛋白酶抑制剂和组织多肽特异性抗原在Ⅲ期宫颈癌随访中的应用

Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.

作者信息

Gitsch G, Kainz C, Joura E, Fröhlich B, Bieglmayr C, Tatra G

机构信息

II. Department of Obstetrics and Gynecology, University of Vienna Medical School, Austria.

出版信息

Anticancer Res. 1992 Jul-Aug;12(4):1247-9.

PMID:1503417

Abstract

189 clinical and serological examinations were performed in 30 patients before treatment and during follow up of squamous cell cervical cancer stage FIGO III. The serum levels of the tumor markers squamous cell carcinoma antigen (SCC), tumor associated trypsin inhibitor (TATI) and tissue polypeptide specific antigen (TPS) were determined. Sensitivity/specificity for SCC was 63%/91%, TATI 54%/74%, TPS 59%/86% and for a combination of SCC and TPS 81%/77%. In 14 women with recurrence of disease SCC showed lead time effects in seven patients in a time range from three to nine months. SCC was pre-therapeutically elevated in nine cases and showed lead time in five of them. Pretherapeutic TPS serum levels were elevated in seven cases. In all of them lead time effects appeared ranging from three to nine months. TPS never showed lead time effects in patients without elevated pretherapeutic levels. A combination of SCC and TPS in our material provided lead time in 10 of 14 cases.

摘要

对30例国际妇产科联盟（FIGO）III期宫颈鳞状细胞癌患者在治疗前及随访期间进行了189次临床和血清学检查。测定了肿瘤标志物鳞状细胞癌抗原（SCC）、肿瘤相关胰蛋白酶抑制剂（TATI）和组织多肽特异性抗原（TPS）的血清水平。SCC的敏感性/特异性为63%/91%，TATI为54%/74%，TPS为59%/86%，SCC与TPS联合检测的敏感性/特异性为81%/77%。在14例疾病复发的女性中，SCC在7例患者中显示出提前期效应，时间范围为3至9个月。治疗前SCC升高的有9例，其中5例显示出提前期效应。治疗前TPS血清水平升高的有7例。在所有这些病例中，提前期效应均出现，时间范围为3至9个月。在治疗前水平未升高的患者中，TPS从未显示出提前期效应。在我们的研究材料中，SCC与TPS联合检测在14例中的10例中显示出提前期效应。